Sunshine Biopharma

Sunshine Biopharma EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sunshine Biopharma (SBFM) as of Oct 31, 2026 is -4.48 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -5.59 M USD — a change of -19.86% (higher).

EBITDA

-4.48 MUSD

YoY

-19.86%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sunshine Biopharma is 2025 -4.48 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sunshine Biopharma was 2024 -5.59 M USD. It decreases by -19.86% higher compared to the previous year.

The Sunshine Biopharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-1.98 M USD
Jan 1, 2019
-627,636.00 USD
Jan 1, 2020
-562,874.00 USD
Jan 1, 2021
-2.43 M USD
Jan 1, 2022
-8.07 M USD
Jan 1, 2023
-4.64 M USD
Jan 1, 2024
-5.59 M USD
Jan 1, 2025
-4.48 M USD
The Sunshine Biopharma EBITDA history
YEAREBITDAYoY
-4.48 MUSD-19.86%
-5.59 MUSD+20.54%
-4.64 MUSD-42.56%
-8.07 MUSD+232.53%
-2.43 MUSD+331.20%
-562,874.00USD-10.32%
-627,636.00USD-68.34%
-1.98 MUSD+133.21%
-850,190.00USD-8.79%
-932,108.00USD+20.07%
-776,277.00USD-55.77%
-1.76 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sunshine Biopharma Stock analysis

What does Sunshine Biopharma do? Sunshine Biopharma Inc., based in Pointe-Claire, Quebec, is a biotechnology company focused on developing and commercializing oncology and antiviral drugs. The company employs 46 full-time staff and operates through two segments: generic prescription pharmaceuticals and over-the-counter products. It develops proprietary drugs such as Adva-27a for pancreatic cancer, K1.1 mRNA for liver cancer, and SBFM-PL4 for antiviral applications. The firm also manages subsidiaries NoraPharma Inc. and Sunshine Biopharma Canada Inc., which handle generic and OTC product portfolios respectively. Sunshine Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunshine Biopharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sunshine Biopharma is -4.48 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sunshine Biopharma changed from -5.59 M USD to -4.48 M USD, representing a -19.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Sunshine Biopharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Sunshine Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Sunshine Biopharma

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Sunshine Biopharma